Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T.
Kuboki Y, et al. Among authors: shirao k.
Br J Cancer. 2023 May;128(10):1897-1905. doi: 10.1038/s41416-023-02212-2. Epub 2023 Mar 4.
Br J Cancer. 2023.
PMID: 36871043
Free PMC article.
Clinical Trial.